Are triplet therapies really living up to their hype as the "standard of care" for multiple myeloma and what else is needed?

Expert Rev Hematol. 2019 Sep;12(9):699-701. doi: 10.1080/17474086.2019.1641403. Epub 2019 Jul 16.

Authors

Martin Schreder¹, Stefan Knop²

Affiliations

¹ First Department of Medicine, Center for Oncology and Hematology, Wilhelminen Hospital , Vienna , Austria.
² Department of Internal Medicine II, Division of Hematology and Medical Oncology, University Hospital Wuerzburg , Wuerzburg , Germany.

PMID: 31287740
DOI: 10.1080/17474086.2019.1641403

No abstract available

Keywords: Autologous stem cell transplantation; induction; multiple myeloma; transplant-ineligible; triplet therapies.

Publication types

Editorial

MeSH terms

Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Hematopoietic Stem Cell Transplantation / methods
Humans
Multiple Myeloma / therapy*
Neoplasm Recurrence, Local / therapy
Secondary Prevention / methods
Transplantation, Autologous / methods